SKB BIO-B (06990) rose nearly 5%, with a 3.42% increase at the time of writing, trading at HK$436 and a turnover of HK$88.673 million. The company recently announced the release of multiple clinical research results at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, from October 17 to 21.

CITIC Securities noted that the company's core product, SKB264, was selected for two oral presentations at ESMO. As a monotherapy, it demonstrated best-in-class (BIC) potential in second-line and beyond (2L+) treatment for EGFR-mutated non-small cell lung cancer (NSCLC), with favorable safety. The indication was approved for market launch in October. Additionally, SKB264 showed significantly superior efficacy compared to chemotherapy in 2L+ treatment for HR+/HER2- breast cancer (BC), with potential approval expected by 2026.

The company also disclosed clinical data for another core product, A166, which outperformed T-DM1 as a monotherapy in 2L+ treatment for HER2+ BC. This indication was also approved for market launch in October.